Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF, a New Plateau -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (1677)	2/7/2003 10:03:11 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 2243

very much on-topic, thanks. it will be fun to follow the candidates. curious....... is English your first language? If not, your grasp is more than impressive.

To: Icebrg who wrote (1677)	2/12/2003 4:09:22 PM
From: Icebrg	Read Replies (2) \| Respond to of 2243

Spectrum's Generic Drug Business. I found the following in an Indian research report, that I stumbled over while trawling the net. "The company filed its first ANDA with USFDA for Ciprofloxacin in Q3 FY 03. It is also planning to file second ANDA for Ofloxacin during this quarter." Erik

To: Icebrg who wrote (1677)	3/28/2003 6:10:51 PM
From: Icebrg	Read Replies (2) \| Respond to of 2243

The identity of the "mysterious" investor pledging some funding - tied to the ANDA filed by Spectrum (SPPI) on behalf of JBCPL for ciproflaxicin - was revealed in the 10K filed today. Perhaps not so surprising was the fact that it turned out to be an Indian entity. More surprising was the fact that it was another Indian manufacturer of generic drugs who is making the investment. Not Spectrum's partner JBCPL, but Lekar Pharma. The plot is thickening. If there is a two-months' acceptance period for ANDAs too, we are getting closer to the first generic moment of truth. (Hint: Do they know how to file an ANDA). The PR stating that the ANDA had been filed was dated February 7. In the meantime the share price has traded rather listlessly. Most of the time slightly below 2 USD. And the market cap. stays consequently at around 3 mUSD. The directors are continuing to buy shares in the company from time to time although the transactions are normally not very big. But still. They buy rather than sell them. Erik Mr. A.P. Mehta Director LEKAR Pharma Limited 83 B & C Sheth Govindrao Smrithi Dr. Annie Besant Road, Worli, Mumbai 400 018 Dear Mr. Mehta, This letter of agreement spells out the basic terms under which Lekar Pharma Limited or its affiliate will invest $1 million into Spectrum Pharmaceuticals, Inc. The investments will be made in two parts contingent upon the achievement of two milestones. The first milestone will be the acceptance by the US Food and Drug Administration of an ANDA filing by Spectrum on behalf of JBCPL for ciproflaxicin, and the investment will be $250,000 in cash for Spectrum shares, based on the closing price of Spectrum stock on the day prior to acceptance by the US Food and Drug Administration. The second milestone will be the approval by the US Food and Drug Administration of the ANDA filing by Spectrum on behalf of JBCPL for ciproflaxicin, and the investment will be $750,000 in cash for Spectrum shares, based on the closing price of Spectrum stock on the day prior to approval by the US Food and Drug Administration. The investment would be subject to approval by the Reserve Bank of India or other appropriate authority under the prevailing laws of India. Agreed to this 26th day of March 2003, by /s/ Rajesh Shrotriya --------------------------------------- Rajesh Shrotriya, M.D. Chairman, Chief Executive Officer